161 related articles for article (PubMed ID: 34835225)
21. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
22. Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.
Gunawardane RN; Nepomuceno RR; Rooks AM; Hunt JP; Ricono JM; Belli B; Armstrong RC
Mol Cancer Ther; 2013 Apr; 12(4):438-47. PubMed ID: 23412931
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor.
Tse KF; Novelli E; Civin CI; Bohmer FD; Small D
Leukemia; 2001 Jul; 15(7):1001-10. PubMed ID: 11455967
[TBL] [Abstract][Full Text] [Related]
24. MerTK activity is not necessary for the proliferation of glioblastoma stem cells.
Hoque M; Wai Wong S; Recasens A; Abbassi R; Nguyen N; Zhang D; Stashko MA; Wang X; Frye S; Day BW; Baell J; Munoz L
Biochem Pharmacol; 2021 Apr; 186():114437. PubMed ID: 33571503
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
26. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
Levis M
Future Oncol; 2014; 10(9):1571-9. PubMed ID: 25145428
[TBL] [Abstract][Full Text] [Related]
27. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
[TBL] [Abstract][Full Text] [Related]
28. MerTK is required for apoptotic cell-induced T cell tolerance.
Wallet MA; Sen P; Flores RR; Wang Y; Yi Z; Huang Y; Mathews CE; Earp HS; Matsushima G; Wang B; Tisch R
J Exp Med; 2008 Jan; 205(1):219-32. PubMed ID: 18195070
[TBL] [Abstract][Full Text] [Related]
29. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
[TBL] [Abstract][Full Text] [Related]
30. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia.
Perelló-Reus CM; Català A; Caviedes-Cárdenas L; Vega-García N; Camós M; Pérez-Torras S; Pastor-Anglada M
Pharmacol Res; 2020 Jan; 151():104556. PubMed ID: 31778791
[TBL] [Abstract][Full Text] [Related]
31. Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells.
Abe M; Pelus LM; Singh P; Hirade T; Onishi C; Purevsuren J; Taketani T; Yamaguchi S; Fukuda S
PLoS One; 2016; 11(7):e0158290. PubMed ID: 27387666
[TBL] [Abstract][Full Text] [Related]
32. Autophosphorylation docking site Tyr-867 in Mer receptor tyrosine kinase allows for dissociation of multiple signaling pathways for phagocytosis of apoptotic cells and down-modulation of lipopolysaccharide-inducible NF-kappaB transcriptional activation.
Tibrewal N; Wu Y; D'mello V; Akakura R; George TC; Varnum B; Birge RB
J Biol Chem; 2008 Feb; 283(6):3618-3627. PubMed ID: 18039660
[TBL] [Abstract][Full Text] [Related]
33. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
34. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
35. Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.
Zhong Y; Qiu RZ; Sun SL; Zhao C; Fan TY; Chen M; Li NG; Shi ZH
J Med Chem; 2020 Nov; 63(21):12403-12428. PubMed ID: 32659083
[TBL] [Abstract][Full Text] [Related]
36. Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.
Moore AS; Faisal A; Mak GWY; Miraki-Moud F; Bavetsias V; Valenti M; Box G; Hallsworth A; de Haven Brandon A; Xavier CPR; Stronge R; Pearson ADJ; Blagg J; Raynaud FI; Chopra R; Eccles SA; Taussig DC; Linardopoulos S
Blood Adv; 2020 Apr; 4(7):1478-1491. PubMed ID: 32282883
[TBL] [Abstract][Full Text] [Related]
37. Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy.
Tormoen GW; Blair TC; Bambina S; Kramer G; Baird J; Rahmani R; Holland JM; McCarty OJT; Baine MJ; Verma V; Nabavizadeh N; Gough MJ; Crittenden M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):93-103. PubMed ID: 32311417
[TBL] [Abstract][Full Text] [Related]
38. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract][Full Text] [Related]
39. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
Hou P; Wu C; Wang Y; Qi R; Bhavanasi D; Zuo Z; Dos Santos C; Chen S; Chen Y; Zheng H; Wang H; Perl A; Guo D; Huang J
Cancer Res; 2017 Aug; 77(16):4402-4413. PubMed ID: 28625976
[TBL] [Abstract][Full Text] [Related]
40. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
